APA (7th ed.) Citation

Wu, C., Niu, X., Wang, X., Su, J., Zhao, H., Lin, M., . . . Yang, L. (2026). Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial. Dermatology & Therapy, 16(7), 3431. https://doi.org/10.1007/s13555-026-01787-x

Chicago Style (17th ed.) Citation

Wu, Chao, et al. "Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial." Dermatology & Therapy 16, no. 7 (2026): 3431. https://doi.org/10.1007/s13555-026-01787-x.

MLA (9th ed.) Citation

Wu, Chao, et al. "Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial." Dermatology & Therapy, vol. 16, no. 7, 2026, p. 3431, https://doi.org/10.1007/s13555-026-01787-x.